Switch theme
Sign up to access all valuation multiples
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
2004
159
LTM Revenue $3.8M
LTM EBITDA -$72.5M
-$12.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Molecular Partners has a last 12-month revenue (LTM) of $3.8M and a last 12-month EBITDA of -$72.5M.
In the most recent fiscal year, Molecular Partners achieved revenue of $6.0M and an EBITDA of -$62.0M.
Molecular Partners expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Molecular Partners valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.8M | XXX | $6.0M | XXX | XXX | XXX |
| Gross Profit | $3.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$72.5M | XXX | -$62.0M | XXX | XXX | XXX |
| EBITDA Margin | -1923% | XXX | -1039% | XXX | XXX | XXX |
| EBIT | -$74.6M | XXX | -$73.5M | XXX | XXX | XXX |
| EBIT Margin | -1978% | XXX | -1232% | XXX | XXX | XXX |
| Net Profit | -$68.8M | XXX | -$64.9M | XXX | XXX | XXX |
| Net Margin | -1826% | XXX | -1087% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Molecular Partners's stock price is CHF 3 (or $4).
Molecular Partners has current market cap of CHF 118M (or $142M), and EV of -CHF 10.8M (or -$12.9M).
See Molecular Partners trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$12.9M | $142M | XXX | XXX | XXX | XXX | $-1.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Molecular Partners has market cap of $142M and EV of -$12.9M.
Molecular Partners's trades at -2.2x EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate Molecular Partners's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Molecular Partners has a P/E ratio of -2.1x.
See valuation multiples for Molecular Partners and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $142M | XXX | $142M | XXX | XXX | XXX |
| EV (current) | -$12.9M | XXX | -$12.9M | XXX | XXX | XXX |
| EV/Revenue | -3.4x | XXX | -2.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | -3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMolecular Partners's last 12 month revenue growth is -18%
Molecular Partners's revenue per employee in the last FY averaged $38K, while opex per employee averaged $0.5M for the same period.
Molecular Partners's rule of 40 is -864% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Molecular Partners's rule of X is -1968% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Molecular Partners and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -18% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1923% | XXX | -1039% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | -864% | XXX | -1057% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1968% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 978% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1332% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Molecular Partners acquired XXX companies to date.
Last acquisition by Molecular Partners was XXXXXXXX, XXXXX XXXXX XXXXXX . Molecular Partners acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Molecular Partners founded? | Molecular Partners was founded in 2004. |
| Where is Molecular Partners headquartered? | Molecular Partners is headquartered in Switzerland. |
| How many employees does Molecular Partners have? | As of today, Molecular Partners has 159 employees. |
| Who is the CEO of Molecular Partners? | Molecular Partners's CEO is Dr. Patrick Amstutz, PhD. |
| Is Molecular Partners publicy listed? | Yes, Molecular Partners is a public company listed on SWX. |
| What is the stock symbol of Molecular Partners? | Molecular Partners trades under MOLN ticker. |
| When did Molecular Partners go public? | Molecular Partners went public in 2014. |
| Who are competitors of Molecular Partners? | Similar companies to Molecular Partners include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Molecular Partners? | Molecular Partners's current market cap is $142M |
| What is the current revenue of Molecular Partners? | Molecular Partners's last 12 months revenue is $3.8M. |
| What is the current revenue growth of Molecular Partners? | Molecular Partners revenue growth (NTM/LTM) is -18%. |
| What is the current EV/Revenue multiple of Molecular Partners? | Current revenue multiple of Molecular Partners is -3.4x. |
| Is Molecular Partners profitable? | Yes, Molecular Partners is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Molecular Partners? | Molecular Partners's last 12 months EBITDA is -$72.5M. |
| What is Molecular Partners's EBITDA margin? | Molecular Partners's last 12 months EBITDA margin is -1923%. |
| What is the current EV/EBITDA multiple of Molecular Partners? | Current EBITDA multiple of Molecular Partners is 0.2x. |
| What is the current FCF of Molecular Partners? | Molecular Partners's last 12 months FCF is -$69.2M. |
| What is Molecular Partners's FCF margin? | Molecular Partners's last 12 months FCF margin is -1835%. |
| What is the current EV/FCF multiple of Molecular Partners? | Current FCF multiple of Molecular Partners is 0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
